Orasis Closes $30MM Series C Round for Phase III Trials and Pre-Commercialization Activities.

News, Orasis

Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the closing of a $30 million Series C financing. The financing was co-led by new investor Bluestem Capital and returning investor Visionary Ventures, with participation from other returning investors Sequoia Capital, SBI (Japan) Innovation Fund, Maverick Ventures, LifeSci Venture Partners and additional investors.

Optometric Management Interviews TearClear CEO Robert Dempsey

News, TearClear

Robert J. Dempsey recently joined TearClear, an emerging global ophthalmic pharmaceutical company with a focus on eye drops that are preserved safely prior to administering dosing, as Chief Executive Officer. Prior to this role, Mr. Dempsey held positions at Shire (Takeda, now Novartis), Bausch + Lomb, Allergan and Inspire Pharmaceuticals. What follows is a Q&A with Mr. Dempsey, where he reveals, among other things, his love of American history.

LinkZoomDetails

Re-Vana Therapeutics

Companies

Re-Vana Therapeutics is developing sustained release ophthalmic therapeutics that can reduce the frequency of intravitreal injections required to treat a wide range of retinal diseases, including neovascular age-related macular degeneration. The Re-Vana platform has the potential to deliver at least 4 to 6 months sustained delivery of a large molecule biologic, including anti-VEGF therapies. Re-Vana’s technology could spur a new generation of glaucoma medications that may reduce or eliminate the need for eye drops by delivering small molecules for 6 to 9 months or longer.